Cardiff Oncology (CRDF) Competitors

Cardiff Oncology logo
$0.84 0.00 (-0.17%)
As of 01:10 PM Eastern
This is a fair market value price provided by Massive. Learn more.

CRDF vs. QTTB, LXEO, BCYC, ALEC, and FATE

Should you buy Cardiff Oncology stock or one of its competitors? Cardiff Oncology's main competitors and comparable companies include Q32 Bio (QTTB), Lexeo Therapeutics (LXEO), Bicycle Therapeutics (BCYC), Alector (ALEC), and Fate Therapeutics (FATE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Cardiff Oncology compare to Q32 Bio?

Q32 Bio (NASDAQ:QTTB) and Cardiff Oncology (NASDAQ:CRDF) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, institutional ownership, risk, media sentiment and dividends.

31.3% of Q32 Bio shares are held by institutional investors. Comparatively, 16.3% of Cardiff Oncology shares are held by institutional investors. 34.5% of Q32 Bio shares are held by insiders. Comparatively, 8.8% of Cardiff Oncology shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Q32 Bio has a beta of 0.45, suggesting that its stock price is 55% less volatile than the broader market. Comparatively, Cardiff Oncology has a beta of 1.57, suggesting that its stock price is 57% more volatile than the broader market.

In the previous week, Cardiff Oncology had 11 more articles in the media than Q32 Bio. MarketBeat recorded 14 mentions for Cardiff Oncology and 3 mentions for Q32 Bio. Cardiff Oncology's average media sentiment score of 0.71 beat Q32 Bio's score of 0.57 indicating that Cardiff Oncology is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Q32 Bio
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Cardiff Oncology
1 Very Positive mention(s)
2 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Q32 Bio has higher revenue and earnings than Cardiff Oncology. Cardiff Oncology is trading at a lower price-to-earnings ratio than Q32 Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Q32 Bio$53.74M4.80$29.82M$3.342.58
Cardiff Oncology$590K111.60-$45.85M-$0.55N/A

Q32 Bio has a net margin of 0.00% compared to Cardiff Oncology's net margin of -6,736.49%. Q32 Bio's return on equity of 17.03% beat Cardiff Oncology's return on equity.

Company Net Margins Return on Equity Return on Assets
Q32 BioN/A 17.03% 15.24%
Cardiff Oncology -6,736.49%-111.80%-81.51%

Q32 Bio currently has a consensus price target of $32.17, indicating a potential upside of 272.73%. Cardiff Oncology has a consensus price target of $7.50, indicating a potential upside of 786.11%. Given Cardiff Oncology's higher probable upside, analysts plainly believe Cardiff Oncology is more favorable than Q32 Bio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Q32 Bio
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.78
Cardiff Oncology
1 Sell rating(s)
3 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.29

Summary

Q32 Bio beats Cardiff Oncology on 12 of the 17 factors compared between the two stocks.

How does Cardiff Oncology compare to Lexeo Therapeutics?

Cardiff Oncology (NASDAQ:CRDF) and Lexeo Therapeutics (NASDAQ:LXEO) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, earnings and risk.

Cardiff Oncology has a beta of 1.57, meaning that its share price is 57% more volatile than the broader market. Comparatively, Lexeo Therapeutics has a beta of 1.64, meaning that its share price is 64% more volatile than the broader market.

In the previous week, Lexeo Therapeutics had 7 more articles in the media than Cardiff Oncology. MarketBeat recorded 21 mentions for Lexeo Therapeutics and 14 mentions for Cardiff Oncology. Cardiff Oncology's average media sentiment score of 0.71 beat Lexeo Therapeutics' score of 0.37 indicating that Cardiff Oncology is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cardiff Oncology
1 Very Positive mention(s)
2 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Lexeo Therapeutics
7 Very Positive mention(s)
5 Positive mention(s)
4 Neutral mention(s)
3 Negative mention(s)
0 Very Negative mention(s)
Neutral

Cardiff Oncology presently has a consensus price target of $7.50, suggesting a potential upside of 786.11%. Lexeo Therapeutics has a consensus price target of $16.43, suggesting a potential upside of 474.43%. Given Cardiff Oncology's higher possible upside, equities research analysts clearly believe Cardiff Oncology is more favorable than Lexeo Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cardiff Oncology
1 Sell rating(s)
3 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.29
Lexeo Therapeutics
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
2 Strong Buy rating(s)
3.00

Cardiff Oncology has higher revenue and earnings than Lexeo Therapeutics. Lexeo Therapeutics is trading at a lower price-to-earnings ratio than Cardiff Oncology, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cardiff Oncology$590K111.60-$45.85M-$0.55N/A
Lexeo TherapeuticsN/AN/A-$99.96M-$1.15N/A

16.3% of Cardiff Oncology shares are owned by institutional investors. Comparatively, 60.7% of Lexeo Therapeutics shares are owned by institutional investors. 8.8% of Cardiff Oncology shares are owned by company insiders. Comparatively, 2.0% of Lexeo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Lexeo Therapeutics has a net margin of 0.00% compared to Cardiff Oncology's net margin of -6,736.49%. Lexeo Therapeutics' return on equity of -44.28% beat Cardiff Oncology's return on equity.

Company Net Margins Return on Equity Return on Assets
Cardiff Oncology-6,736.49% -111.80% -81.51%
Lexeo Therapeutics N/A -44.28%-40.81%

Summary

Lexeo Therapeutics beats Cardiff Oncology on 9 of the 16 factors compared between the two stocks.

How does Cardiff Oncology compare to Bicycle Therapeutics?

Cardiff Oncology (NASDAQ:CRDF) and Bicycle Therapeutics (NASDAQ:BCYC) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, media sentiment, earnings, institutional ownership, dividends, analyst recommendations, valuation and risk.

In the previous week, Cardiff Oncology had 8 more articles in the media than Bicycle Therapeutics. MarketBeat recorded 14 mentions for Cardiff Oncology and 6 mentions for Bicycle Therapeutics. Bicycle Therapeutics' average media sentiment score of 0.95 beat Cardiff Oncology's score of 0.71 indicating that Bicycle Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cardiff Oncology
1 Very Positive mention(s)
2 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Bicycle Therapeutics
2 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Cardiff Oncology has a beta of 1.57, suggesting that its share price is 57% more volatile than the broader market. Comparatively, Bicycle Therapeutics has a beta of 1.59, suggesting that its share price is 59% more volatile than the broader market.

16.3% of Cardiff Oncology shares are owned by institutional investors. Comparatively, 86.2% of Bicycle Therapeutics shares are owned by institutional investors. 8.8% of Cardiff Oncology shares are owned by company insiders. Comparatively, 22.0% of Bicycle Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Cardiff Oncology presently has a consensus price target of $7.50, indicating a potential upside of 786.11%. Bicycle Therapeutics has a consensus price target of $13.57, indicating a potential upside of 324.11%. Given Cardiff Oncology's higher possible upside, equities analysts plainly believe Cardiff Oncology is more favorable than Bicycle Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cardiff Oncology
1 Sell rating(s)
3 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.29
Bicycle Therapeutics
1 Sell rating(s)
4 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.40

Cardiff Oncology has higher earnings, but lower revenue than Bicycle Therapeutics. Bicycle Therapeutics is trading at a lower price-to-earnings ratio than Cardiff Oncology, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cardiff Oncology$590K111.60-$45.85M-$0.55N/A
Bicycle Therapeutics$72.86M3.08-$218.96M-$2.03N/A

Bicycle Therapeutics has a net margin of -169.75% compared to Cardiff Oncology's net margin of -6,736.49%. Bicycle Therapeutics' return on equity of -26.02% beat Cardiff Oncology's return on equity.

Company Net Margins Return on Equity Return on Assets
Cardiff Oncology-6,736.49% -111.80% -81.51%
Bicycle Therapeutics -169.75%-26.02%-22.30%

Summary

Bicycle Therapeutics beats Cardiff Oncology on 10 of the 15 factors compared between the two stocks.

How does Cardiff Oncology compare to Alector?

Cardiff Oncology (NASDAQ:CRDF) and Alector (NASDAQ:ALEC) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and dividends.

Cardiff Oncology presently has a consensus price target of $7.50, suggesting a potential upside of 786.11%. Alector has a consensus price target of $5.10, suggesting a potential upside of 99.22%. Given Cardiff Oncology's higher probable upside, research analysts plainly believe Cardiff Oncology is more favorable than Alector.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cardiff Oncology
1 Sell rating(s)
3 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.29
Alector
2 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.43

Cardiff Oncology has a beta of 1.57, suggesting that its stock price is 57% more volatile than the broader market. Comparatively, Alector has a beta of 0.61, suggesting that its stock price is 39% less volatile than the broader market.

In the previous week, Cardiff Oncology had 7 more articles in the media than Alector. MarketBeat recorded 14 mentions for Cardiff Oncology and 7 mentions for Alector. Alector's average media sentiment score of 1.05 beat Cardiff Oncology's score of 0.71 indicating that Alector is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cardiff Oncology
1 Very Positive mention(s)
2 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Alector
1 Very Positive mention(s)
4 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

16.3% of Cardiff Oncology shares are owned by institutional investors. Comparatively, 85.8% of Alector shares are owned by institutional investors. 8.8% of Cardiff Oncology shares are owned by insiders. Comparatively, 8.3% of Alector shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Alector has a net margin of 23.87% compared to Cardiff Oncology's net margin of -6,736.49%. Alector's return on equity of 112.21% beat Cardiff Oncology's return on equity.

Company Net Margins Return on Equity Return on Assets
Cardiff Oncology-6,736.49% -111.80% -81.51%
Alector 23.87%112.21%18.37%

Cardiff Oncology has higher earnings, but lower revenue than Alector. Cardiff Oncology is trading at a lower price-to-earnings ratio than Alector, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cardiff Oncology$590K111.60-$45.85M-$0.55N/A
Alector$21.05M18.11-$142.93M$0.357.31

Summary

Alector beats Cardiff Oncology on 10 of the 16 factors compared between the two stocks.

How does Cardiff Oncology compare to Fate Therapeutics?

Cardiff Oncology (NASDAQ:CRDF) and Fate Therapeutics (NASDAQ:FATE) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk, media sentiment and profitability.

Fate Therapeutics has a net margin of -1,941.09% compared to Cardiff Oncology's net margin of -6,736.49%. Fate Therapeutics' return on equity of -73.92% beat Cardiff Oncology's return on equity.

Company Net Margins Return on Equity Return on Assets
Cardiff Oncology-6,736.49% -111.80% -81.51%
Fate Therapeutics -1,941.09%-73.92%-45.16%

Cardiff Oncology currently has a consensus price target of $7.50, suggesting a potential upside of 786.11%. Fate Therapeutics has a consensus price target of $5.80, suggesting a potential upside of 468.63%. Given Cardiff Oncology's higher possible upside, equities research analysts clearly believe Cardiff Oncology is more favorable than Fate Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cardiff Oncology
1 Sell rating(s)
3 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.29
Fate Therapeutics
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.50

16.3% of Cardiff Oncology shares are held by institutional investors. Comparatively, 97.5% of Fate Therapeutics shares are held by institutional investors. 8.8% of Cardiff Oncology shares are held by insiders. Comparatively, 4.7% of Fate Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Cardiff Oncology had 12 more articles in the media than Fate Therapeutics. MarketBeat recorded 14 mentions for Cardiff Oncology and 2 mentions for Fate Therapeutics. Cardiff Oncology's average media sentiment score of 0.71 beat Fate Therapeutics' score of 0.51 indicating that Cardiff Oncology is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cardiff Oncology
1 Very Positive mention(s)
2 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Fate Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Cardiff Oncology has higher earnings, but lower revenue than Fate Therapeutics. Cardiff Oncology is trading at a lower price-to-earnings ratio than Fate Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cardiff Oncology$590K111.60-$45.85M-$0.55N/A
Fate Therapeutics$6.65M18.65-$136.32M-$1.03N/A

Cardiff Oncology has a beta of 1.57, meaning that its share price is 57% more volatile than the broader market. Comparatively, Fate Therapeutics has a beta of 2.65, meaning that its share price is 165% more volatile than the broader market.

Summary

Fate Therapeutics beats Cardiff Oncology on 9 of the 16 factors compared between the two stocks.

Get Cardiff Oncology News Delivered to You Automatically

Sign up to receive the latest news and ratings for CRDF and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRDF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CRDF vs. The Competition

MetricCardiff OncologyBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$65.66M$4.00B$7.66B$11.73B
Dividend YieldN/A3.63%2.47%4.46%
P/E Ratio-1.5324.7134.0030.04
Price / Sales111.4115.848.445.70
Price / CashN/A22.9521.0121.90
Price / Book2.354.194.483.75
Net Income-$45.85M-$24.10M$3.51B$394.12M
7 Day Performance10.41%-7.66%-5.93%-5.63%
1 Month Performance-6.23%-5.73%-4.31%-6.93%
1 Year Performance-58.58%-6.16%-1.15%-7.12%

Cardiff Oncology Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CRDF
Cardiff Oncology
1.9449 of 5 stars
$0.85
-0.2%
$7.50
+787.6%
-58.9%$65.66M$590KN/A31
QTTB
Q32 Bio
3.818 of 5 stars
$9.34
+1.0%
$32.17
+244.4%
+276.9%$267.03M$53.74M3.7222
LXEO
Lexeo Therapeutics
2.8959 of 5 stars
$3.14
+8.7%
$16.43
+423.2%
-69.8%$265.01MN/AN/A59
BCYC
Bicycle Therapeutics
2.7463 of 5 stars
$3.77
+4.4%
$13.57
+260.0%
-50.5%$260.37M$72.86MN/A288
ALEC
Alector
4.6834 of 5 stars
$2.46
+7.4%
$4.63
+88.0%
+106.5%$254.58M$21.05M7.03103

Related Companies and Tools


This page (NASDAQ:CRDF) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners